- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Lincoln Pharma gets Gujarat FDA approval to manufacture Hydroxychloroquine and Hydroxychloroquine Sulfate Tablets to fight COVID19
Gujarat: Lincoln Pharmaceuticals Limited informed that it has received approval to manufacture Hydroxychloroquine (HCQ) among other critical drugs to fight COVID 19. The company received approval from the Food & Drug Control Administration, Gujarat to manufacture varied dosages of Hydroxychloroquine Tablets and Hydroxychloroquine Sulfate Tablets among others at its plant in Khatraj...
Gujarat: Lincoln Pharmaceuticals Limited informed that it has received approval to manufacture Hydroxychloroquine (HCQ) among other critical drugs to fight COVID 19. The company received approval from the Food & Drug Control Administration, Gujarat to manufacture varied dosages of Hydroxychloroquine Tablets and Hydroxychloroquine Sulfate Tablets among others at its plant in Khatraj in Ahmedabad.
After necessary approval from the Directorate General of Foreign Trade (DGFT) company will be able to export these products.
Food & Drug Control Administration, Gujarat approved manufacture of following drugs from Lincoln Pharma's Khatraj facility.
ï‚· Hydroxychloroquine Sulfate Tablets USP in 200 MG, 300 MG and 400 MG dosages.
ï‚· Hydroxychloroquine Tablets IP in 200 MG, 300 MG and 400 MG dosages respectively.
Mr Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, "We have all the necessary infrastructure at our state-of-the-art manufacturing facility at Khatraj, Ahmedabad and look to expedite the commercial production of the approved drugs at the earliest. Company is committed to fighting the COVID-19 pandemic and working closely with the governments and relevant stakeholders to ensure uninterrupted supply of medicines.
Company has also constituted a task force to handle the distribution of medicines and essential drugs with the primary objective of dealing with any kind of emergency or distress situation by COVID-19."
HCQ is a prescription based drug commonly recommended to Corona patients under treatment for the disease. India is the largest producer of HCQ and taking a lead in supplying this to the world in this time of crisis.
Lincoln Pharmaceuticals Ltd develops and manufactures affordable and innovative medicines for healthier lives. The company has developed 300 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others.
Read also: COVID-19 Testing Kits: Mylab Joins Hands With Syngene International
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751